Singapore markets closed

Straits Times Index
3,331.70
+5.42(+0.16%)
S&P 500
5,465.41
-3.89(-0.07%)
Dow
39,035.85
-76.31(-0.20%)
Nasdaq
17,769.29
+51.63(+0.29%)
Bitcoin USD
61,779.82
+66.72(+0.11%)
CMC Crypto 200
1,276.66
-7.12(-0.55%)

ITCI Nov 2024 60.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.2600

+0.4800

(+26.97%)

As of 09:30AM EDT. Market open.

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.